Berkshire Biomedical Today Launched Its First Public Investment Campaign to Support the Advancement of Its Revolutionary COPA™ Technology DALLAS, Feb. 24, 2025 /PRNewswire/ — Berkshire Biomedical Corporation (“Berkshire” or the “Company”), focused on developing its proprietary drug…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.